Rapid Alteplase Administration Improves Functional Outcomes in Patients With Stroke due to Large Vessel Occlusions.
Aged
Aged, 80 and over
Arterial Occlusive Diseases
/ drug therapy
Disability Evaluation
Female
Humans
Male
Meta-Analysis as Topic
Middle Aged
Plasminogen Activators
/ therapeutic use
Stroke
/ drug therapy
Thrombectomy
Time-to-Treatment
Tissue Plasminogen Activator
/ therapeutic use
Treatment Outcome
brain ischemia
humans
ischemia
stroke
thrombectomy
thrombolysis
Journal
Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
pubmed:
15
2
2019
medline:
26
11
2019
entrez:
15
2
2019
Statut:
ppublish
Résumé
Background and Purpose- We report the relation of onset-to-treatment time and door-to-needle time with functional outcomes and mortality among patients with ischemic stroke with imaging-proven large vessel occlusion treated with intravenous alteplase. Methods- Individual patient-level data from the HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) collaboration were pooled from 7 trials that randomized patients to mechanical thrombectomy added to best medical therapy versus best medical therapy alone. Analysis was restricted to patients who received alteplase directly at the endovascular hospital. The primary outcome was disability defined on the modified Rankin Scale at 3 months. Results- Among 601 patients, mean age was 66.0 years (SD, 13.9), 50% were women, and median National Institutes of Health Stroke Scale score was 17. Onset-to-treatment time was median 125 minutes (interquartile range, 90-170). Door-to-treatment time was median 38 minutes (interquartile range, 26-55). Each 60-minute onset-to-treatment time delay was associated with greater disability at 90 days; the odds of functional independence (modified Rankin Scale, 0-2) at 90 days was 0.82 (95% CI, 0.66-1.03). With each 60-minute delay in door-to-needle time; the odds of functional independence was 0.55 (95% CI, 0.37-0.81) at 90 days. The absolute decline in the rate of excellent outcome (modified Rankin Scale, 0-1 at 90 days) was 20.3 per 1000 patients treated per 15-minute delay in door-to-needle time. The adjusted absolute risk difference for a door-to-needle time <30 minutes versus 30 to 60 minutes was 19.3% for independent outcome (number-needed-to-treat ≈5 to gain 1 additional good outcome). Symptomatic intracranial hemorrhage occurred in 3.4% of patients, without a significant time dependency: odds ratio, 0.74 (95% CI, 0.43-1.28). Conclusions- Faster intravenous thrombolysis delivery is associated with less disability at 3 months among patients with large vessel occlusion.
Identifiants
pubmed: 30760169
doi: 10.1161/STROKEAHA.118.021840
doi:
Substances chimiques
Plasminogen Activators
EC 3.4.21.-
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
645-651Subventions
Organisme : Department of Health
ID : HTA/14/08/47
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn